公开(公告)号：US20230203051A1

公开(公告)日：2023-06-29

申请号：US18176848

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew Mulhem ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder

IPC: C07D487/14 ,  A61K9/00 ,  A61K47/12 ,  A61K47/38 ,  A61K31/4985

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K47/12 ,  A61K47/38 ,  A61K31/4985 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

公开(公告)号：US20230312594A1

公开(公告)日：2023-10-05

申请号：US18176664

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew Mulhem ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder ,  Aileen L. Pangan ,  Jaclyn Kay Anderson ,  In-Ho Song ,  Jose Jeffrey V. Enejosa

IPC: C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthrritis), kits, methods of synthesis, and products-by -process.